JMSACL is the continuation of the journal Clinical Mass Spectrometry (CMS). Changing the name of a journal is not an easy process; however, we feel the change was necessary to reflect a broadening of the association's aims and scope. Over the past several years, we have gradually realized that our mission is not merely to Accelerate the Implementation of Mass Spectrometry in the Clinic, but to improve patient care and outcome altogether. While initially viewing mass spectrometry as the ultimate key to improving patient care, it has became clear that optimal clinical analysis will involve integration of multiple technologies (e.g., MS, immunoassays, SPR, NMR, etc). In light of this, we shifted our mission statement to reflect our core interest, Technology & Data Science for Enhanced Patient Care, and adjusted the name of the association to Mass Spectrometry & Advances in the Clinical Lab* in order to embrace this new vision of technological inclusion. This revised perspective was projected onto the journal, and it became clear that a name change was needed. In this case, that change achieved dual effect: a broadening of scope to achieve the core goal of improving patient care and outcome, and brand alignment with its sponsor organization.
*previously Mass Spectrometry : Applications to the Clinical Laboratory
All existing publications with CMS will be held under, and affiliated with, JMSACL. In line with Elsevier's standard procedure, the journal name listed with your publication will not change. However, on the article page, there will be a statement explaining that the name of the journal has now changed. As the JMSACL develops and is indexed with PubMed, all existing papers from CMS will also be listed under a green open archiving policy. There is no action you need to take at this time. Thank you for your contribution to CMS and we hope to welcome future manuscripts from yourself and colleagues for publication in the JMSACL. Please do not hesitate to contact us if you have any queries or concerns about the upcoming transition.
JMSACL operates under Platinum Open Access with a Pay-What-You-Can publishing model. While MSACL guarantees all publishing costs, authors are encouraged to support a portion of these costs, if they are able. Currently, MSACL is responsible to Elsevier for $900 per full-length article. Any contribution above $49 is recognized on the MSACL Contributors page. Authors will be provided the opportunity to make a contribution once their manuscript has been accepted for publication.
JMSACL publishes peer-reviewed articles addressing mass spectrometry and other advances in Laboratory Medicine and Pathology with a focus on development of diagnostic and related applications, including data science, to improve patient outcomes and reduce healthcare costs.
Beyond communication of the application of technologies in the routine clinical diagnostic setting, by publishing critically validated analytical protocols, the journal also addresses the translation of experimental techniques and analytical research into patient care, and the use of these technologies in clinical research and routine patient management. The scope of the journal is not restricted to any particular technology, but covers the entire range of technologies and advancements that are expected to impact the clinical lab.
The journal encourages submissions having a clear path to patient care, including basic and translational research, and animal studies.
Subject areas covered by the journal include, but are not restricted to:
Clinical Studies and Implementation
Error Sources, Risk Assessment and Patient Safety
Harmonization and Standardization
Metabolomics and Metabolic Analyses
Method Development and Validation
Protein Variant Detection
Reference Methods and Materials
Regulatory Aspects in Diagnostic Applications
Therapeutic Drug Monitoring
Reviews, graphical reviews, mini-reviews, original research papers, short communications (e.g., letters, case studies, protocols, application notes, developed poster presentations), guidelines and best practice documents, tutorials, invited editorials, opinions.
This journal currently has no page charges. All papers submitted are published as Open Access. Contributions to MSACL to support the Open Access initiative are welcomed and recognized on the MSACL Contributors page.
:: The Journal of Mass Spectrometry & Advances in the Clinical Lab (JMSACL) is owned by MSACL and licensed to Elsevier for publication.